TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with milk (first dose 250 mg)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with egg (first dose 250 mg)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with milk (first dose 100 mg)
Study: 10719311
Drug: DBPCFC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC with egg (first dose 100 mg)
Study: 10719311
Drug: DBPCFC (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC (final dose or open challenge) with egg
Study: 10719311
Drug: DBPCFC (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC (final dose or open challenge) with milk
Study: 10719311
Drug: DBPCFC (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC (final dose or open challenge) with soy
Study: 10719311
Drug: DBPCFC (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC (final dose or open challenge) with wheat
Study: 10719311
Drug: DBPCFC (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC (final dose or open challenge) with peanut
Study: 10719311
Drug: DBPCFC (final
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBPCFC (final dose or open challenge) with fish
Study: 10719311
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose reactions severity
Study: 10719311
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of PST and RAST with dose and severity
Study: 8658221
Drug: PSK or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSK or OK‐432 (biological response modifiers) added to chemotherapy
Study: 1329251
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UF) 15,000 units, three subcutaneous injections (Group 1)
Study: 1329251
Drug: Parnaparin 6,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin 6,400 units, single injection (Group 2)
Study: 1329251
Drug: Parnaparin 12,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parnaparin 12,800 units, single injection (Group 3)
Study: 3862230
Drug: Sugar free
Normalized name: Laxmar Sugar Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar free chewing gum containing 0.25 mg fluoride
Study: 31415087
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of fezolinetant twice daily for 12 weeks
Study: 20839388
Drug: Codeine (p.o.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine (p.o. 30 mg q.d.s., n = 8)
Study: 20839388
Drug: Methylnaltrexone (s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone (s.c. 0.30 mg/kg, n = 16)
Study: 20839388
Drug: Combined MNTX
Normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combined MNTX and codeine (same doses and routes, n = 16)
Study: 10930153
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy including protease inhibitors (PI)
Study: 10930153
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination therapy including non-nucleoside reverse transcriptase inhibitors (NNRTI)
Study: 10930153
Drug: Dual nucleoside
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual nucleoside therapy
Study: 9058214
Drug: Limited intentional
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited intentional normovolemic hemodilution (LINH) during the prebypass period until a hematocrit of 34% was obtained, with succinyl-linked gelatin infusion (n = 39)
Study: 3527407
Drug: levamisole, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: levamisole, 2.5 mg/kg, 2 days of each week in addition to chemotherapy
Study: 26775184
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and fentanyl combined as a single solution (group 2, 55 patients)
Study: 26775184
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and fentanyl administered separately (group 1, 57 patients)
Study: 18479744
Drug: Extended-release metoprolol
Normalized name: metoprolol Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release metoprolol succinate (n=4174)
Study: 8238220
Drug: 5-fluorouracil (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil (mean total dose, 24.8 mg; mean number of injections, 5.0 ± 1.3)
Study: 2436011
Drug: 2.9 g
Normalized name: ZINC OXIDE 12.9 g in 100 g TOPICAL LOTION [UV Skin Recovery SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.9 g of the amylase inhibitor
Study: 2436011
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g of the amylase inhibitor
Study: 26081485
Drug: EAA mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAA mixture with 20% L-Leucine (Group A)
Study: 26081485
Drug: EAA mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAA mixture with 40% L-Leucine (Group B)
Study: 18433921
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei Shirota (6.5 x 10(9)) 3 times daily for 4 weeks
Study: 20076952
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg orally for 5 days)
Study: 11801578
Drug: AmBisome 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmBisome 3 or 5 mg/kg/day
Study: 11801578
Drug: Abelcet 5
Normalized name: Abelcet 5 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abelcet 5 mg/kg/day
Study: 11801578
Drug: Lipid formulations
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid formulations (general)
Study: 7869686
Drug: Initial injection
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial injection of diluted local anesthetic (1:10 with saline)
Study: 27479106
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy (CBGT) with e-mail support
Study: 27479106
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Group Therapy (CBGT) without e-mail support
Study: 24549763
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) with 1,000 impulses
Study: 13677125
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g Owen Mumford monofilament sensory testing
Study: 9346691
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin bolus (666 mU . kg‐1) followed by infusion at 500 mU.m‐2.min‐1 until 3 hours after portal vein unclamping.
Study: 9346691
Drug: No exogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exogenous insulin administered.
Study: 27296819
Drug: Aclidinium 400
Normalized name: aclidinium 400 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 400 μg/formoterol 12 μg
Study: 24532007
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg tideglusib
Study: 24532007
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg tideglusib
Study: 15908835
Drug: MAS XR
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAS XR 10 mg once daily, with 10 mg weekly dose increases to a maximum of 30 mg/d
Study: 10917210
Drug: Intratumoral injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral injection of a replication-defective adenoviral expression vector containing wild-type p53
Study: 9347431
Drug: ondansetron 100
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ondansetron 100 mcg/kg
Study: 9347431
Drug: droperidol 75
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: droperidol 75 mcg/kg
Study: 9347431
Drug: metoclopramide 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 250 mcg/kg
Study: 8191134
Drug: Miocamycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miocamycin (15 mg/kg/day bid per os)
Study: 8191134
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (600,000 or 1,200,000 units, single injection)
Study: 3083712
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg orally) with SNP
Study: 24445685
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg oral n-acetyl cysteine twice daily
Study: 22730694
Drug: Complex treatment
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex treatment group
Study: 20556437
Drug: Paravertebral block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral block (PVB) with 5 mL of 0.5% levobupivacaine
Study: 16167284
Drug: Tobramycin enhanced
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin enhanced viscosity ophthalmic solution (3 mg/mL) given twice daily (BID) for 7 days
Study: 16167284
Drug: Tobramycin 0.3%
Normalized name: TOBRAMYCIN 0.3% OINT,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin 0.3% ophthalmic solution (3 mg/mL) given four times daily (QID) for 7 days
Study: 10087016
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of caffeine consumed as a single dose in the morning
Study: 10087016
Drug: Caffeine maintenance
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine maintenance doses of 100, 300, and 600 mg/day
Study: 10087016
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg caffeine/day with lower doses (200, 100, 50, 25, and 0 mg/day)
Study: 10087016
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day for 1, 3, 7, or 14 days
Study: 7612769
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg intravenously (4 doses starting at induction of anaesthesia)
Study: 7612769
Drug: Hyoscine transdermally
Normalized name: HYOSCINE HYDROBROMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine transdermally (patch placed behind the ear at 0600 h on the day of operation)
Study: 28033244
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (100,000 units single oral dose)
Study: 23903022
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg bolus followed by 1 mg·kg·h infusion (low dose)
Study: 23903022
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg bolus followed by 16 mg·kg·h infusion (high dose)
Study: 15899163
Drug: 105 mg
Normalized name: menthol 105 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg of elemental iron daily p.o.
Study: 15899163
Drug: 105 mg
Normalized name: menthol 105 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg of elemental iron daily and 5 mg of folic acid daily p.o.
Study: 15899163
Drug: No vitamin
Normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No vitamin supplements (control group)
Study: 14565892
Drug: Treatment completers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment completers (N = 18)
Study: 14565892
Drug: Follow-up (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up (6 months post-treatment)
Study: 10037634
Drug: Beta carotene
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta carotene (42 mg, or 7000 micrograms retinol equivalents)
Study: 8650042
Drug: d-penicillamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-penicillamine treatment
Study: 1784628
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg miglitol
Study: 30144629
Drug: Standard In-Office
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard In-Office Cognitive Processing Therapy (CPT)
Study: 30144629
Drug: In-Home CPT
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-Home CPT (provider delivers treatment in participant's home)
Study: 22244363
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (SUP)
Study: 20102884
Drug: Plasminogen activator
Normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasminogen activator inhibitor-1 (PAI-1) antigen
Study: 17375984
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human porphobilinogen deaminase (P 9808) at doses of 0.5, 1, 2, and 4 mg/kg bodyweight
Study: 16327349
Drug: Sprotte 24
Normalized name: BRUSSELS SPROUT
DrugBank: Brussels sprout (DB10642)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sprotte 24 g atraumatic spinal needle
Study: 9457145
Drug: Buprenorphine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (4 or 12 mg)
Study: 9457145
Drug: Buprenorphine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (4 mg)
Study: 9457145
Drug: Methadone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (20 or 65 mg)
Study: 2649300
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg nicardipine t.i.d.
Study: 2649300
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg hydrochlorothiazide b.i.d.
Study: 37848
Drug: MIF (melanocyte-stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIF (melanocyte-stimulating hormone-release inhibiting factor) 200 mg i.v.
Study: 30797746
Drug: Endobronchial coil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial coil treatment (QVM+)
Study: 30797746
Drug: Endobronchial coil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial coil treatment (QVM-)
Study: 15592334
Drug: AMG 531
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 531 (10.0 microg/kg, intravenous)
Study: 15592334
Drug: AMG 531
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 531 (2.0 microg/kg, subcutaneous)
Study: 15592334
Drug: AMG 531
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 531 (1.0 microg/kg, intravenous and subcutaneous)
Study: 8831412
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pilsicainide
Study: 30194618
Drug: Hysterosalpingogram (HSG)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hysterosalpingogram (HSG) vs Saline infusion sonohysterography (SIS)
Study: 25701561
Drug: Intensive five-drug
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive five-drug cART regimen (raltegravir 400 mg and maraviroc 150 mg twice daily, plus tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, darunavir 800 mg, and ritonavir 100 mg once daily)
Study: 25701561
Drug: Standard triple-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple-drug cART regimen (tenofovir disoproxil fumarate 300 mg, emtricitabine 200 mg, darunavir 800 mg, and ritonavir 100 mg once daily)
Study: 25701561
Drug: Intensive five-drug
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive five-drug cART regimen
Study: 25701561
Drug: Standard triple-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple-drug cART regimen
Study: 10677921
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of 350 mg Euphyllin Retard at 8:00 A.M.
Study: 10677921
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of 350 mg Euphyllin Retard at 8:00 P.M.
Study: 1421063
Drug: Ephedrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (5 mg/dose)
Study: 1421063
Drug: CaCl2 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CaCl2 (200 mg/dose)
Study: 27689688
Drug: Navy beans
Normalized name: navy kidney bean allergenic extract
DrugBank: Kidney bean (DB10639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navy beans (NB) consumption (35 g/day)
Study: 27689688
Drug: Rice bran
Normalized name: Rice bran
DrugBank: Rice bran (DB14361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice bran (RB) consumption (30 g/day)
Study: 16115394
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - fluticasone propionate (FP) 250 microg bid for moderate asthma and 375 microg bid for severe asthma (Group G)
Study: 16115394
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - half doses of fluticasone propionate (FP) 125 microg bid for moderate asthma and 125 microg in the morning, 250 microg in the evening for severe asthma (Group H)
Study: 16115394
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - fluticasone propionate (FP) (Group G)
Study: 16115394
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) - half doses of fluticasone propionate (FP) (Group H)
Study: 10802126
Drug: Milnacipran (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran (50 mg bid)
Study: 29561511
Drug: Biannual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual treatment of children under 12 with azithromycin (20 mg/kg up to 1 g in adults)
Study: 29561511
Drug: Annual treatment
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual treatment of everyone with azithromycin (20 mg/kg up to 1 g in adults)
Study: 29561511
Drug: Biannual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biannual treatment of children under 12 with azithromycin
Study: 21753160
Drug: Daily prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily prednisone (0.75 mg/kg/day)
Study: 21753160
Drug: Weekend prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekend prednisone (10 mg/kg/wk)
Study: 16714386
Drug: Recombinant methionyl
Normalized name: Recombinant methionyl human bdnf
DrugBank: Recombinant methionyl brain-derived neurotrophic factor (DB16970)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant methionyl human leptin (r-metHuLeptin) administered during fasting
Study: 16714386
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered during fasting
Study: 11706112
Drug: Levodopa plus
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa plus dopa decarboxylase inhibitor
Study: 10567624
Drug: Inhaled ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ozone (200 ppb)
Study: 8704426
Drug: Zhuchun Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhuchun Pill (ZCP)
Study: 2490739
Drug: Preparation the
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation the afternoon before surgery
Study: 2490739
Drug: Preparation the
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation the morning of surgery
Study: 778433
Drug: Coenzyme Q7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q7 intravenous injection (50 to 100 mg daily for 3 to 35 days)
Study: 778433
Drug: Coenzyme Q7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coenzyme Q7 oral administration (60 mg daily for 14 to 196 days)
Study: 778433
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 oral administration (30 mg daily for 7 to 182 days)
Study: 31331568
Drug: Almond sachet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond sachet (40 g/day for 20 days)
Study: 29173737
Drug: Positive Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive Family Interaction Therapy (PFIT)
Study: 21258153
Drug: AZD3480 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 5 mg
Study: 21258153
Drug: AZD3480 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 20 mg
Study: 21258153
Drug: AZD3480 35/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3480 35/100 mg
Study: 21258153
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg (active comparator)
Study: 16391376
Drug: Eptifibatide (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (180 micro/kg bolus x 2, 10 minutes apart, then 2 micro/kg/min infusion over 18 hours)
Study: 16391376
Drug: Low-dose unfractionated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose unfractionated heparin (60 Units per kg, target ACT 200-250 sec)
Study: 16391376
Drug: High-dose unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose unfractionated heparin (100 Units per kg, target ACT 300-400 sec)